HR1922Referred to Committee

Ensuring Access to Essential Drugs Act

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2025-03-06
Introduced
2
Cosponsors
HR
ⓘ
Type

Sponsor

Andrew R. Garbarino
Andrew R. Garbarino
Republican · NY · Representative
Votes with party: 94.5% (585 recorded votes)

Full profile: /officials/G000597

Source: Congress.gov · FEC

Cosponsors (2)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

2025-03-06

Source: Congress.gov

Plain-English Summary

This bill would address drug availability and affordability by establishing requirements to ensure Americans can access essential medications without excessive delays or costs. The legislation likely includes measures to prevent drug shortages, regulate pricing practices, or expand insurance coverage for critical medicines that treat serious health conditions. It would affect patients needing medications, pharmaceutical companies, insurance companies, and healthcare providers.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Subjects

Health

Full Bill Text

Verbatim text published on Congress.gov via GovInfo. Use Cmd+F / Ctrl+F to search within this excerpt.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 1922 Introduced in House (IH)] <DOC> 119th CONGRESS 1st Session H. R. 1922 To amend title XVIII of the Social Security Act to exempt certain drugs from the part D manufacturer discount program under the Medicare program. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES March 6, 2025 Mr. Garbarino (for himself, Mrs. Harshbarger, and Mr. Suozzi) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________ A BILL To amend title XVIII of the Social Security Act to exempt certain drugs from the part D manufacturer discount program under the Medicare program. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Ensuring Access to Essential Drugs Act''. SEC. 2. EXEMPTING CERTAIN DRUGS FROM THE PART D MANUFACTURER DISCOUNT PROGRAM UNDER THE MEDICARE PROGRAM. Section 1860D-14C(g)(2) of the Social Security Act (42 U.S.C. 1395w-114c(g)(2)) is amended-- (1) in subparagraph (A), by striking ``and'' at the end; (2) in subparagraph (B), by striking the period and inserting ``; and''; and (3) by adding at the end the following new subparagraph: ``(C) does not include an orally administered drug-- ``(i) for which a new drug application was approved under section 505 of the Federal Food, Drug, and Cosmetic Act; and ``(ii) that has been granted a narrow exception permitting reclassification as a noninnovator multiple source drug under the Medicaid drug rebate program by the Centers for Medicare & Medicaid Services.''. <all>
Open clean-text viewRead on Congress.gov →

Related legislation

Bills by the same sponsor or covering overlapping subjects.